She Spent 6 Summers Hiding the Smell. Then a Microbiologist Showed Her What Her Doctor Missed.
Her dermatologist gave her a tube of hydrocortisone and a referral to a nutritionist. A clinical mycologist gave her something the U.S. Surgeon General deployed in 1942.
Women who used to buy drugstore antifungal creams every summer are not switching to prescription antifungals. They are not booking dermatology procedures. They are not booking skin removal surgery. They are just stopping.
If you have been one of them, you are not alone. And if you are reading this with skepticism, good. Every product you have ever tried has earned that skepticism. This piece is not going to ask you to believe anything. It is going to show you the math and let you decide.
She Spent 6 Summers Convinced It Was Her Fault.
Marlene Beasley is 52. She is a hospital billing manager in Charlotte, North Carolina. She has worked in healthcare for 28 years. She has watched doctors write notes about overweight patients she sat next to in the waiting room. She knows what those notes say.
The first summer it happened to her, she was 46. The skin under her belly fold turned red and started weeping clear fluid by the second week of June. By the third week, it was sticking to her work shirts.
She bought her first tube of Lotrimin from CVS. It worked for four days. Then the rash came back.
She bought Gold Bond. It absorbed the moisture for an hour. Then it turned into paste and shredded the skin worse.
She tried cornstarch. She tried Zeasorb. She tried hydrocortisone. She tried the prescription antifungal her primary care doctor wrote her after her first visit. She tried switching to cotton underwear. She tried sleeping with a fan blowing on her stomach. She tried stuffing rolled-up paper towels under her belly fold at her desk.
By the end of summer two, her bathroom cabinet had eleven half-used drugstore tubes in it.
By summer three, she had gone to a dermatologist. The dermatologist gave her another tube of hydrocortisone and a printout about portion control. She paid the $158 copay and walked out.
By summer four, she had gone to two more dermatologists. One told her to lose 30 pounds. One asked if she was washing the area properly.
By summer five, she stopped going to dermatologists.
By summer six, she had spent over $1,200 on drugstore tubes, copays, and prescription antifungals that did not work. She had cried in three exam rooms. She had cried in her car twice. She had cried in the dressing room at Belk trying on a tank top she put back on the rack.
She thought it was her fault.
It was not.
The Mycologist Who Stopped Trusting the Protocol.
Dr. Ellen Voss is 47. She is a clinical mycologist. She spent 15 years at a Midwestern clinical research institute studying one specific organism: Candida albicans.
Candida is the fungus responsible for most chronic skin-fold rashes in adult women. Voss did not study it because it was glamorous research. She studied it because nobody else was paying attention to it.
In 2019, she published a paper in a peer-reviewed clinical mycology journal. The paper documented something the drugstore industry has spent twenty years pretending was not true.
The yeast in skin-fold infections does not just sit on the surface.
It mutates.
Under heat, sweat, and friction, the yeast cells transition into a different shape. Round cells stretch into elongated structures called hyphae. The hyphae grow downward. They penetrate the top layer of skin. They reach into the living tissue underneath.
That is what bleeds. That is what weeps. That is what smells.
Voss's paper was cited 47 times. Mostly by other mycologists. Mostly in academic journals nobody outside the field reads. None of the citations came from drugstore brand formulators. None came from the dermatology associations that train the doctors who write hydrocortisone scripts.
She kept publishing. The drugstore shelf did not change.
In 2022, she resigned from the institute. She took a consulting role at a private clinic in Minneapolis. She told her colleagues she was tired of pretending the protocols were working.
What Standard Treatments Actually Do. And What They Cannot.
Here is what is not controversial.
Antifungal creams work. Lotrimin uses clotrimazole. Monistat uses miconazole. Both are azole antifungals targeting the same surface yeast. Studies have measured this effect for forty years.
Powders work. Gold Bond and Zeasorb absorb moisture. Cornstarch absorbs even more.
Hydrocortisone works. It suppresses inflammation. It calms redness fast.
Nobody is saying these products do nothing.
But here is what your doctor will not tell you.
Each one of these products treats one cause of intertrigo. Skin-fold rash has three.
The three causes are moisture, friction, and fungus. They feed each other in a loop. Sweat creates moisture. Moisture softens the skin. Softened skin tears under friction. Yeast invades the tears. The yeast triggers more inflammation. Inflammation creates more sweat. The loop runs every day, in every fold, all summer.
To break the loop, you have to interrupt all three causes at once.
Antifungal creams kill yeast. But the cream itself is greasy. Greasy creams trap moisture. Trapped moisture feeds the yeast cycle the cream is supposed to break.
Powders absorb moisture. But sweat keeps coming. Sweat plus powder turns into paste. Paste creates friction. Friction shreds the skin worse than friction alone. And the powder itself feeds the yeast. Cornstarch is corn. Yeast eats corn.
Hydrocortisone reduces inflammation for a few days. Then the skin starts to thin. Thin skin tears faster. The next flare-up is worse than the last.
Every drugstore cream feeds the moisture problem. Every drugstore powder feeds the yeast or the friction problem. Every steroid weakens the skin you are trying to protect.
There has not been a drugstore product released in the last twenty years that addresses all three causes at the same time. The physics of a standard cream and the physics of a standard powder make it impossible.
So What About Dermatology Procedures? Or Prescription Antifungals?
This is the question every woman asks next. If drugstore creams treat one cause, what about the medical-grade options?
Voss has heard this question for fifteen years. The answer is not what most women want to hear.
Prescription antifungals like terbinafine and ketoconazole are stronger than Lotrimin. They kill more yeast on contact. But the cream base under them is the same occlusive vehicle. The vehicle traps moisture. The yeast comes back. The script stops working.
Hydrocortisone scripts are stronger than the over-the-counter version. The skin-thinning happens faster. Some women report depigmentation after six months of daily use. Studies in the dermatology literature show the recurrence rate after a steroid taper is essentially universal.
Surgical removal of redundant skin folds is real. Panniculectomy and abdominoplasty cost between $8,000 and $15,000 depending on the surgeon. Insurance covers the procedure only when documented medical complications meet specific thresholds. Most women who ask are denied.
Voss puts it this way. "These women were not looking for a more aggressive procedure. They were looking for a completely different approach."
The approach existed. It had existed for eighty years. Almost nobody in the drugstore industry was using it.
The Bathroom Cabinet That Cost $1,200.
This is what Marlene's six summers cost her, in receipts she still has.
Eleven tubes of Lotrimin and Monistat: $154.
Three powder containers (Gold Bond, Zeasorb, store-brand cornstarch): $42.
Two prescription antifungal scripts with copay: $178.
Six dermatology visits including the two follow-ups: $830.
Total: $1,204.
Plus 14 work shirts ruined by weeping fluid that did not wash out. Plus four months of sleep lost to night sweats and burning. Plus the wedding she did not attend. Plus the swim trip with her nieces she made up an excuse to skip.
She kept buying because she kept hoping. The cabinet did not get smaller. The rash did not go away.
The Yeast-to-Hyphal Shift Your Doctor Never Tested For.
This is the part that should make you furious.
Candida albicans is what scientists call a dimorphic fungus. Dimorphic means it has two body shapes. Most people have only seen the first shape. Round, microscopic, sitting on the skin surface, mostly harmless.
The second shape is what causes the bleeding.
When the temperature on your skin rises above a certain point, and when sweat pools in a fold for more than a few hours, and when fabric or skin rubs against the area, the yeast switches shape. The round cells stretch out. They become long. They become elongated tubes called hyphae.
Hyphae do not sit on the surface.
Hyphae grow downward. They press into the top layer of skin. They push past the epidermis into the dermis underneath. They are root-like structures. They are alive. They are looking for food.
Your skin is the food.
That is what is bleeding.
That is what is weeping.
That is what smells like sour bread when you change shirts at three in the afternoon.
Voss documented this in her 2019 paper. The morphological switch from yeast to hyphae takes between 24 and 48 hours under the right heat and moisture conditions. Once hyphae penetrate the dermis, surface creams cannot reach them. The cream sits on top. The roots stay underneath.
This is the sentence Voss wishes every dermatologist would read.
Any treatment that does not block the morphological switch is treating the wrong stage of the infection.
Drugstore antifungal creams kill round-shape yeast on the surface. They cannot kill the hyphae underneath. The hyphae are protected by the cream's own occlusive layer. The hyphae keep growing. The rash comes back.
Hydrocortisone calms inflammation but does not touch the hyphae. The hyphae keep growing. The rash comes back.
Powders dry the surface but feed the hyphae and abrade the skin. The hyphae keep growing. The rash comes back.
For thirty-five years, every drugstore brand has marketed the surface-killing solution. None of them has marketed the morphological-switch-blocking solution.
Voss knew the morphological-switch-blocking solution existed.
It had existed since 1942.
What the U.S. Surgeon General Solved in 1942.
In the spring of 1942, the U.S. Surgeon General had a problem.
American troops were deploying into the Pacific theater. The South Pacific climate was 90 percent humidity at sea level. The men were sweating through three uniforms a day. Within six weeks of arrival, a significant share of soldiers were reporting fungal infections in skin folds and groin areas that would not respond to standard antifungal treatments.
The infections were not just uncomfortable. They were operationally disabling. Soldiers with raw, weeping skin in their groin area could not march. Could not carry packs. Could not engage.
The Army turned to a compound that had been documented in medical literature for thirty years but never deployed at scale: a fatty acid derived from the castor plant called Undecylenic Acid.
What made it different from every other antifungal of the era was specific. It did not just kill yeast on the surface. It interfered with the morphological switch. It blocked the yeast cells from transitioning into the elongated hyphal form. Without that transition, the infection could not penetrate the dermis. Without dermal penetration, the rash could not become operationally disabling.
By the mid-1940s, military medics in tropical theaters were issued the compound for prophylactic use. It remained in clinical antifungal protocols through the postwar decades and stayed in specialty formulations through to the present.
It never made it onto the standard drugstore shelf.
There were two reasons. First, Undecylenic Acid requires precise concentration calibration to actually block the morphological switch. Below a certain percentage, it kills surface yeast like any other antifungal but does not interfere with the transition. Above a certain percentage, it irritates intact skin. The drugstore industry, which prefers wide margins of safety and shelf-stable formulations, defaulted to weaker azole antifungals like clotrimazole.
Second, the cream vehicle most drugstore brands use to deliver any antifungal is occlusive. It seals the skin. It traps moisture. Trapped moisture is exactly the condition that triggers the morphological switch in the first place. Even at the right concentration of Undecylenic Acid, a standard cream vehicle would re-create the conditions that produce the hyphae the active was supposed to block.
The active had existed for eighty years.
The vehicle had not.
The Formulation Voss Said Should Not Have Existed.
The phone call came in October 2024. A private formulator in Pittsburgh wanted to send Voss a sample.
He had read her 2019 paper. He told her he had spent three years on a vehicle problem. He thought he had solved it.
What he had built was a cream-to-powder formulation. The cream went on like any other antifungal cream. But within 60 seconds, the cream evaporated. What it left behind was a dry, micronized powder barrier on the surface of the skin.
Voss had spent fifteen years in the literature on this exact problem. She had never seen a cream that evaporated into a powder. She had read three abstract proposals for cream-to-powder vehicles in pharmaceutical engineering journals over the years. None of the abstracts had become commercial products.
She agreed to test it.
She had three patients in her clinic agree to try it as part of an early-access protocol. All three had documented chronic recurring intertrigo lasting more than two years. All three had cycled through the standard drugstore stack and at least one prescription antifungal. All three were in the middle of a summer flare-up.
By day 3, all three had stopped weeping.
By day 14, all three had recovered surface skin.
When the next humidity trigger arrived six weeks later, none of the three had a recurrence.
Voss measured the active concentration in the formulation. It was in the precise window the wartime military trials had established. The vehicle was holding the concentration stable through the dry-down phase. The powder barrier was preventing fresh moisture from re-triggering the morphological switch.
She asked the formulator one question. Was anyone else making this?
He told her no.
Introducing NOVEXA DryFold Defense Intertrigo Relief Cream.
The formulator's company is called NOVEXA. The product line is DryFold Defense. The formal product name is Intertrigo Relief Cream.
Voss endorsed it within three months of her clinical observations.
It is the only commercial product on the U.S., Canadian, and Australian market currently delivering Undecylenic Acid in a cream-to-powder vehicle at military-grade concentration. The formula also includes Witch Hazel and micronized Zinc Oxide. The packaging is a 60-milliliter squeeze tube. The application is twice daily, morning and evening, on clean and dry skin.
What you are looking at, structurally, is the active that the U.S. Surgeon General deployed in 1942, finally married to a vehicle that does not undo its own work.
Voss puts it this way. "The reason Undecylenic Acid stayed in clinical use for eighty years and not on the drugstore shelf was the vehicle problem. NOVEXA is the first commercial formulation I have seen that solved both pieces."
What's Inside, And Why Each Active Matters.
The protocol is designed for repeat application during humidity-trigger seasons. Long-term use does not thin the skin like steroid creams or build resistance like prescription antifungals.
There are five actives in the formulation. Here is what each one does.
Undecylenic Acid
This is the active the Surgeon General deployed in 1942. It is a fatty acid that interferes with the morphological switch in Candida albicans. At the right concentration, it does not just kill surface yeast. It blocks the yeast cells from transitioning into the elongated hyphal form that penetrates your skin. The concentration in NOVEXA matches the precise window that the wartime military trials established. Below that window, the active behaves like a standard antifungal. In that window, it blocks the cellular transition that has been driving your recurrence.
Witch Hazel
Voss called this the unsung hero. Witch hazel is an astringent. It tightens the surface of the skin and reduces the redness and inflammation caused by hyphal penetration. Unlike steroid creams, it does not thin the skin. It calms the area without weakening it.
Zinc Oxide
This is the anti-friction layer. After the dry-down phase, micronized zinc oxide forms part of the protective barrier between skin folds. Unlike older zinc oxide formulations that paste and shred under friction, the micronized form integrates into the powder barrier and holds through movement.
The Cream-to-Powder Vehicle
This is the part that took thirty years to engineer. The cream goes on like any other topical product. Then, within 60 seconds, the water phase evaporates and what is left behind is a dry, breathable powder barrier. The vehicle is the reason the Undecylenic Acid actually works in this product when it has not worked in any other commercial formulation. The cream phase delivers the active deep into the micro-cracks where hyphae take root. The powder phase prevents fresh moisture from re-triggering the morphological switch. Cream and powder do different jobs. The vehicle does both jobs in 60 seconds. Engineers spent thirty years on this problem because no other vehicle is physically capable of doing both jobs in one application.
Micronized Powder Barrier
This is what is left on your skin after the dry-down. It is invisible under clothing. It does not paste. It does not abrade. It does not turn into cement when you sweat. It holds for 8 to 12 hours under normal movement and heat conditions. You reapply morning and evening. The barrier rebuilds every time.
If you have spent more than three summers cycling through drugstore creams and powders, the protocol that broke the cycle for the women in this report is available below.
CHECK AVAILABILITY12,000 Women Have Already Broken the Cycle.
More than twelve thousand women in the United States, Canada, and Australia have ordered NOVEXA since it became available.
NOVEXA's customer service team has tracked feedback from a subset of those women aged 35 to 65 across six weeks of twice-daily application. The feedback covered plus-size women with chronic recurring intertrigo, perimenopausal and postmenopausal women with new-onset symptoms, and women with Type 2 diabetes whose elevated blood glucose had been feeding chronic Candida infection.
The most common pattern reported was a visible reduction in weeping by day 3.
Most also reported full surface skin recovery within 14 days.
When the next humidity trigger hit, most did not recur.
Voss has continued to consult on the protocol's development. She has not published a follow-up paper yet. She told us she is waiting for two-year recurrence data before she will commit to a peer-reviewed framing. But she sent us the interim observations she felt comfortable sharing.
Their Words, Not Ours.
These four women represent four distinct patterns NOVEXA's customer service team most often encounters: chronic plus-size sufferers, women in hormonal transition, diabetic patients, and active mothers with new-onset post-pregnancy intertrigo. All four broke their cycle with the same protocol.
Names changed for privacy. Quoted with permission.
WARNING: The Hyphal Recurrence Cycle Compounds.
This is not alarm. This is what the literature documents.
Once the morphological switch from yeast to hyphae has happened in a skin fold, the recurrence cycle does not reset between flare-ups. The dermal architecture remembers. Each subsequent cycle starts deeper than the last.
Voss flagged three windows that determine how this plays out.
Surface weeping stabilizes at chronic baseline. The skin in the fold develops a leathery texture from constant moisture exposure. Hyphal infection re-roots in the dermis after each surface flare-up. This is the window most women try to manage with drugstore creams and powders. The cycle keeps running underneath the surface treatment.
Secondary bacterial infection becomes a measurable risk. This is particularly serious for diabetic women whose elevated blood glucose feeds both yeast and bacteria simultaneously. Cellulitis cases rise notably during humid summer weeks in the case-series literature. The window for non-invasive intervention narrows.
Skin depigmentation and scarring begin to set in patterns that are harder to reverse. Some women report permanent skin discoloration in the affected folds even after the active infection clears.
The best time to break the cycle was last summer.
The second best time is before the next humidity trigger.
Every week of compounded cycles is a week the dermal architecture deteriorates further.
Day 3. Week 2. Week 6.
The protocol Marlene followed is the same one in clinical use under Voss's continued observation.
CHECK AVAILABILITYMarlene Spent $1,200 in Six Years on Drugstore Cycles. Treating the Cause Once Costs Less Than Three Failed Cycles.
The math here is not complicated.
Six summers of drugstore cycling cost Marlene $1,204 in receipts plus $830 in dermatology copays. That is $2,034 spent on protocols that did not interrupt the recurrence cycle one time.
If she had spent the same money on a protocol that addressed all three causes, blocked the morphological switch, and broke the cycle within 60 days, the math would have ended at summer one.
This is the principle Voss returns to with every patient she sees. Treating the cause once costs less than three failed cycles of treating the symptom.
The drugstore industry has built its margins on the cycle. The product that breaks the cycle does not extend the cycle. It ends it. There is no recurring revenue model in a protocol that works.
Your skin folds are not a budget item. They are an organ. The math has been working against you for years. It does not have to keep working against you.
NOVEXA offers a 60-day money-back guarantee. That window was not chosen for marketing reasons. It was chosen for biological reasons.
The hyphal recurrence cycle takes 30 to 45 days minimum from one trigger to the next under typical summer humidity conditions. To know whether a treatment has actually broken the cycle, you have to see the next humidity trigger come and go without recurrence. A 30-day guarantee would not get you past the second cycle. You could not actually know if the protocol was working.
A 60-day window gets you past the next humidity trigger. You see if the cycle has been broken.
If you do not see the cycle break within the 60-day window, you contact NOVEXA for a full refund. No questions asked. No photos required. No medical documentation. The protocol either broke the cycle for you or it did not. You decide. You get refunded.
As of this writing, the production batch of NOVEXA DryFold Defense Intertrigo Relief Cream is running below the projected demand window for the upcoming summer humidity season. The next production run will not complete in time for the early-summer trigger period. Operators have asked us to note the timing for readers who want to start the protocol before the early-summer trigger period.
18
·14 min
22
·2 hr
4
·1 hr
31
·3 hr